Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: To compare the oncological outcomes of radical chemotherapy (R-CT), abdominal radical hysterectomy (ARH), and neoadjuvant chemotherapy and radical surgery (NACT) for International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIIC cervical cancer, according to histological types: squamous cell carcinoma (SCC) and adenocarcinoma (AC)/adenosquamous cell carcinoma (ASC). METHODS: A comparison of 5-year overall survival (OS) and disease-free survival (DFS) was performed for the SCC and AC/ASC subgroups for the three initial treatments, assessed using Kaplan-Meier and Cox proportional hazards regression analysis and validated using propensity score matching (PSM). RESULTS: The study included 4086 patients: R-CT, n = 1913; ARH, n = 1529; and NACT, n = 644. AC/ASC had a lower survival rate (63.7%) than SCC (73.6%) and a higher recurrence and mortality rate (36.3% and 26.4%, respectively). The 5-year OS and DFS rates were different in the SCC group for R-CT, ARH, and NACT (OS: 69.8% vs. 80.8% vs. 73.0%, p < 0.001; DFS: 66.7% vs. 70.7% vs. 56.4%, p < 0.001), also in the AC/ASC group (OS: 46.1% vs. 70.6% vs. 55.6%, p < 0.001; DFS: 42.7% vs. 64.6% vs. 40.8%, p < 0.001). As for initial treatment, survival outcomes were worse for AC/ASC treated with R-CT and ARH than for SCC (both p < 0.05), with no group differences between the two treated with NACT. CONCLUSION: Initial treatment influences oncological prognosis for patients with FIGO 2018 stage IIIC cervical cancer. ARH is an alternative treatment for stage IIIC cervical SCC and AC/ASC, and NACT needs to be chosen with caution, moreover, R-CT for AC/ASC requires careful selection.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study
- Date Crossref
- 28/09/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Dongguan University of Technology pays non établi dans la noticeUniversité ou école supérieure
-
Nanfang Hospital Department of Obstetrics and Gynecology pays non établi dans la noticeÉtablissement de santé
-
Dongguan Polytechnic Department of Midwifery pays non établi dans la noticeUniversité ou école supérieure
-
Southern Medical University Department of Obstetrics and Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
China-Japan Friendship Hospital Department of General Surgery pays non établi dans la noticeÉtablissement de santé
-
Xijing Hospital Department of Obstetrics and Gynecology pays non établi dans la noticeÉtablissement de santé
-
Shanxi Provincial Cancer Hospital Department of Gynecologic Oncology pays non établi dans la noticeÉtablissement de santé
-
Army Medical University Department of Obstetrics and Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
Xinqiao Hospital pays non établi dans la noticeÉtablissement de santé
-
Zhengzhou University Department of Gynecologic Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Henan Cancer Hospital pays non établi dans la noticeÉtablissement de santé
-
Shenzhen Maternity and Child Healthcare Hospital pays non établi dans la noticeÉtablissement de santé
Dongguan University of Technology, Department of Obstetrics and Gynecology — Nanfang Hospital et Department of Midwifery — Dongguan Polytechnic, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.